Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

22-03-2023 | Opioids | Invited Review

Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies

Authors: Juliana Mendes Rocha, José A. S. Reis, José Carlos Bouso, Jaime E. C. Hallak, Rafael G. dos Santos

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2023

Abstract

Ibogaine is a psychoactive alkaloid derived from the west-African shrub Tabernanthe iboga. Western cultures are increasing the interest for the substance due to its claimed anti addictive properties, although the evidence supporting this effect is still preliminary. The use of ibogaine often occurs with no medical supervision in uncontrolled settings, and its use has been associated with several reports of severe adverse events. This review aims to evaluate the clinical studies of ibogaine, with a focus on administration settings, to elucidate specific criteria that may promote safer contexts for ibogaine use. A systematic review of the literature was conducted based on PRISMA guidelines. PubMed, Scielo, ClinicalTrials.gov and Core.ac.uk electronic databases were searched, and clinical studies published until November 17, 2022, were retrieved. The final synthesis included 12 sources. Information about general characteristics of the studies, adverse effects, screening of participants and setting characteristics were summarized and discussed. It is concluded that the use of controlled settings, supported by trained professionals and equipment allowing for rigorous medical, psychiatric, and cardiac monitoring, are essential to promote the safety of patients receiving ibogaine.

Available only for authorised users

Alper KR (2001) Chapter 1 Ibogaine: A review. The Alkaloids: Chemistry and Biology. Academic Press, Elsevier, pp 1–38

Brown TK (2013) Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev 6:3–16. https://doi.org/10.2174/15672050113109990001CrossRefPubMed

Alper KR, Lotsof HS, Kaplan CD (2008) The ibogaine medical subculture. J Ethnopharmacol 115:9–24. https://doi.org/10.1016/j.jep.2007.08.034CrossRefPubMed

Alper KR, Lostoff H (2007) The use of ibogaine in the treatment of addictions. In: Winkelman M, Robert T (eds) Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport, CT, Praeger Perspectives

Rezvani AH, Overstreet DH, Leef YW (1995) Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav 52:615–620. https://doi.org/10.1016/0091-3057(95)00152-MCrossRefPubMed

Mash DC, Kovera CA, Buck BE et al (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 844:274–292CrossRefPubMed

Belgers M, Leenaars M, Homberg JR et al (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Transl Psychiatry 6:e826–e826. https://doi.org/10.1038/tp.2016.71CrossRefPubMedPubMedCentral

He DY, McGough NNH, Ravindranathan A et al (2005) Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25:619–628. https://doi.org/10.1523/JNEUROSCI.3959-04.2005CrossRefPubMedPubMedCentral

Rezvani AH (1995) Suppressing effect of 12-hydroxyibogamine, the primary metabolite of Ibogaine, on alcohol intake in rats. Alcohol Clin Exp Res 15A:

10.

Sheppard SG (1994) A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 11:379–385. https://doi.org/10.1016/0740-5472(94)90049-3CrossRefPubMed

11.

Luciano D (1998) Observations on treatment with ibogaine. Am J Addict 7:89–89. https://doi.org/10.1111/j.1521-0391.1998.tb00472.xCrossRefPubMed

12.

Schenberg EE, de Castro Comis MA, Chaves BR et al (2014) Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol 28:993–1000. https://doi.org/10.1177/0269881114552713CrossRefPubMed

13.

Dos Santos RG, Bouso JC, Hallak JEC (2017) The antiaddictive effects of ibogaine: a systematic literature review of human studies. J Psychedelic Stud 1:20–28. https://doi.org/10.1556/2054.01.2016.001CrossRef

14.

Köck P, Froelich K, Walter M et al (2022) A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subste Abuse Treat 138:108717. https://doi.org/10.1016/j.jsat.2021.108717CrossRef

15.

Wilkins C, dos Santos RG, Solá J et al (2017) Detoxification from methadone using low, repeated, and increasing doses of ibogaine: a case report. J Psychedelic Studies 1:29–34. https://doi.org/10.1556/2054.01.2017.005CrossRef

16.

Hartogsohn I, Petranker R (2022) Set and setting in microdosing: an oft-overlooked principle. Psychopharmacology 239:3771–3777. https://doi.org/10.1007/s00213-022-06249-8CrossRefPubMed

17.

Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573. https://doi.org/10.1097/00005053-196312000-00007CrossRefPubMed

18.

Hartogsohn I (2017) Constructing drug effects: a history of set and setting. Drug Sci Policy and Law 3:1–17. https://doi.org/10.1177/205032451668332CrossRef

19.

Carhart-Harris RL, Roseman L, Haijen E et al (2018) Psychedelics and the essential importance of context. J Psychopharmacol 32:725–731. https://doi.org/10.1177/0269881118754710CrossRefPubMed

20.

Koenig X, Hilber K (2015) The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 20:2208–2228. https://doi.org/10.3390/molecules20022208CrossRefPubMedPubMedCentral

21.

Litjens RPW, Brunt TM (2016) How toxic is ibogaine? Clin Toxicol 54:297–302. https://doi.org/10.3109/15563650.2016.1138226CrossRef

22.

Meisner JA, Wilcox SR, Richards JB (2016) Ibogaine-associated cardiac arrest and death: case report and review of the literature. Therap Adv Psychopharmacol 6(2):95–98. https://doi.org/10.1177/2045125315626073CrossRef

23.

Schep LJ, Slaughter RJ, Galea S, Newcombe D (2016) Ibogaine for treating drug dependence. What is a safe dose? Drug Alcohol Depend 166:1–5. https://doi.org/10.1016/j.drugalcdep.2016.07.005CrossRefPubMed

24.

Ona G, Rocha JM, Bouso JC et al (2022) The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020). Psychopharmacology 239:1977–1987. https://doi.org/10.1007/s00213-021-05964-yCrossRefPubMed

25.

Alper KR, Stajić M, Gill JR (2012) Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 57:398–412. https://doi.org/10.1111/j.1556-4029.2011.02008.xCrossRefPubMed

26.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:N71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

27.

Mash DC, Kovera CA, Pablo J et al (2000) Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 914:394–401. https://doi.org/10.1111/j.1749-6632.2000.tb05213.xCrossRefPubMed

28.

Prior L, Prior SL (2014) Ibogaine effect on cocaine craving and use in dependent patients - a double-blind, placebo-controlled pilot study. Jacobs J Addict Therap 1:003

29.

Glue P, Lockhart M, Lam F et al (2015) Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol 55:189–194. https://doi.org/10.1002/jcph.404CrossRefPubMed

30.

Glue P, Winter H, Garbe K et al (2015) Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. J Clin Pharmacol 55:680–687. https://doi.org/10.1002/jcph.471CrossRefPubMed

31.

Glue P, Cape G, Tunnicliff D et al (2016) Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin Pharmacol Drug Dev 5:460–468. https://doi.org/10.1002/cpdd.254CrossRefPubMed

32.

Forsyth B, Machado L, Jowett T et al (2016) Effects of low dose ibogaine on subjective mood state and psychological performance. J Ethnopharmacol 189:10–13. https://doi.org/10.1016/j.jep.2016.05.022CrossRefPubMed

33.

DemeRx IB, Inc. (2021 - ) A Study of Oral Ibogaine in Opioid Withdrawal. Identifier: NCT05029401. https://clinicaltrials.gov/ct2/show/NCT05029401

34.

International Center for Ethnobotanical Education, Research, and Service (ICEERS) (2020 -) Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification. Identifier: NCT04003948. https://clinicaltrials.gov/ct2/show/NCT04003948

35.

University of São Paulo (USP) (2022 - ) Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: the First Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial. Identifier: NCT03380728. https://clinicaltrials.gov/ct2/show/NCT03380728

36.

Alper KR, Lotsof HS, Frenken GM et al (1999) Treatment of acute opioid withdrawal with ibogaine. Am J Addict 8:234–242. https://doi.org/10.1080/105504999305848CrossRefPubMed

37.

Mash DC, Kovera CA, Pablo J et al (2001) Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol 56:155–171. https://doi.org/10.1016/s0099-9598(01)56012-5CrossRefPubMed

38.

Mash DC, Duque L, Page B, Allen-Ferdinand K (2018) Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Front Pharmacol. https://doi.org/10.3389/fphar.2018.00529CrossRefPubMedPubMedCentral

39.

Knuijver T, Schellekens A, Belgers M et al (2022) Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 117:118–128. https://doi.org/10.1111/add.15448CrossRefPubMed

40.

Hildyard C, Macklin P, Prendergast B, Bashir Y (2016) A case of qt prolongation and torsades de pointes caused by ibogaine toxicity. J Emerg Med 50:e83–e87. https://doi.org/10.1016/j.jemermed.2015.06.051CrossRefPubMed

41.

Paling FP, Andrews LM, Valk GD et al (2012) Life-threatening complications of ibogaine: three case reports. Neth J Med 70:422–424PubMed

42.

Pleskovic A, Gorjup V, Brvar M, Kozelj G (2012) Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol 50:157–157. https://doi.org/10.3109/15563650.2011.647031CrossRef

43.

Vlaanderen L, Martial LC, Franssen EJF et al (2014) Cardiac arrest after ibogaine ingestion. Clin Toxicol 52:642–643. https://doi.org/10.3109/15563650.2014.927477CrossRef

44.

National Institutes on Drug Abuse (US) (2020). Common Comorbidities with Substance Use Disorders Research Report. National Institutes on Drug Abuse (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK571451/. Access in: November 7, 2022

45.

Bouso JC, Fornís I, Vilamala MV et al (2020) An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers. Arch Clin Psychiatry (São Paulo) 47:51–54. https://doi.org/10.1590/0101-60830000000231CrossRef

46.

Breuer L, Kasper BS, Schwarze B et al (2015) “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. J Med Case Rep 9:243. https://doi.org/10.1186/s13256-015-0731-4CrossRefPubMedPubMedCentral

47.

Gallo C, Renzi P, Loizzo S et al (2009) Tabernanthe iboga: a comprehensive review. Pharmacologyonline 3:906–920

48.

Antonio T, Childers SR, Rothman RB et al (2013) Effect of Iboga Alkaloids on µ-Opioid Receptor-coupled g protein activation. PLoS ONE 8:e77262. https://doi.org/10.1371/journal.pone.0077262CrossRefPubMedPubMedCentral

49.

Hittner JB, Quello SB (2004) Combating substance abuse with ibogaine: pre- and posttreatment recommendations and an example of successive model fitting analyses. J Psychoactive Drugs 36:191–199. https://doi.org/10.1080/02791072.2004.10399729CrossRefPubMed

Title: Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies
Authors: Juliana Mendes Rocha
José A. S. Reis
José Carlos Bouso
Jaime E. C. Hallak
Rafael G. dos Santos
Publication date: 22-03-2023
Publisher: Springer Berlin Heidelberg
Keywords: Opioids
Opioids
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2023
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-023-01590-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2023

Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options

New treatment strategies for mental health

White matter predicts tDCS antidepressant effects in a sham-controlled clinical trial study

mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development

Tübinger Training for Autism Spectrum Disorders (TüTASS): a structured group intervention on self-perception and social skills of children with autism spectrum disorder (ASD)

TDCS at home for depressive disorders: an updated systematic review and lessons learned from a prematurely terminated randomized controlled pilot study